@article{oai:hama-med.repo.nii.ac.jp:00004017,
 author = {吉見, 亘弘 and 石川, 竜司 and 曽根, 大貴 and 池羽, 宇宙 and 内山, 広大 and 下平, 有希 and 松田, 慈 and 山口, 裕貴 and 細川, 誠二 and 松井, 和夫 and 峯田, 周幸},
 journal = {耳鼻咽喉科臨床　補冊 = Practica oto-rhino-laryngologica. Suppl.},
 month = {Feb},
 note = {浜松医科大学医学部耳鼻咽喉科・頭頸部外科学教室　峯田周幸教授退任記念論文集〜症例から学ぶ〜, Festschrift for Professor Hiroyuki Mineta In Hornor of His Retirement as Chairman of Hamamatsu University School of Medicine, Epistaxis is a clinically important symptom. All doctors are required to know how to provide appropriate treatment for epistaxis. We report on the results of epidemiologic studies and factors identified as affecting the risk of rebleeding in patients with epistaxis at our hospital. The subjects were 352 patients (221 males, 131 females) who visited the Otolaryngology outpatient department of Hamamatsu University Hospital with the chief complaints of epistaxis during the 5-year period from January 1, 2014, to December 31, 2018. The most commonly encountered were cases with idiopathic epistaxis. In regard to relationships of the age, sex, antiplatelet/anticoagulant drug therapy, bleeding site, blood pressure, presence of allergic rhinitis, etc., with the risk of rebleeding, there was a significant association between the site of bleeding (especially high risk in cases with posterior bleeding and bleeding from the middle turbinate and middle nasal passages) and the risk of rebleeding (P<0.01).},
 pages = {139--143},
 title = {鼻出血症例の検討},
 volume = {156},
 year = {2021}
}